Hugues Bultot, CEO of Univercells, joins the Belgian business delegation to further develop collaborative efforts and activities with Indian biopharmaceutical experts
Their Majesties King Philippe and Queen Mathilde of Belgium arrived in New Delhi on Nov. 5, initiating a seven-day State Visit to India at the gracious invitation of the President of India. Counting itself amongst the 174-member strong official delegation accompanying the Royal couple on the State Visit, Univercells will be in the company of some of the most notable Belgian leaders in industry, press and academia.
Univercells’ CEO and co-founder, Hugues Bultot, joins the 86 Belgian companies represented on this visit, aiming to strengthen existing collaborations between the two countries and promote trade and investment ties. Following a first seminar on Personnalised Healthcare for All held in New Delhi, Mr. Bultot will participate in the Life Sciences and Healthcare Seminar organized by AWEX in Mumbai, presenting existing Belgo-Indian alliances and opportunities for collaboration between Belgian and Indian companies.
Univercells is honored to have this opportunity to participate in such a high-quality event, connecting with players at the forefront of innovation, to nurture and forge the promising and successful relationships and collaborations shaping India’s biomanufacturing landscape.
This visit commemorates the 70th anniversary of friendship between the two countries, marked by the establishment of diplomatic relations between India and Belgium through the opening of the first Belgian embassy in New Delhi in 1947. As time now has shown, India has grown to become Belgium’s second largest export destination and third largest trading partner outside the European Union.
The Indian biotechnology industry is flourishing, now ranked amongst the top 12 biotech destinations worldwide, with a growth rate exceeding 20% CAGR1). Its bio-pharmaceutical segment, accounting for USD 4.2 billion revenue in 2015, draws its talent from top-ranked universities and eminent players with strong track records in API manufacturing, Biologics and biosimilars development, and cell and gene therapy.
1)Compound Annual Growth Rate